Journal article
Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy
B Zeng, APJ Middelberg, A Gemiarto, K MacDonald, AG Baxter, M Talekar, D Moi, KM Tullett, I Caminschi, MH Lahoud, R Mazzieri, R Dolcetti, R Thomas
Journal of Clinical Investigation | AMER SOC CLINICAL INVESTIGATION INC | Published : 2018
DOI: 10.1172/JCI96791
Abstract
Non-antigen-specific stimulatory cancer immunotherapies are commonly complicated by off-target effects. Antigen-specific immunotherapy, combining viral tumor antigen or personalized neoepitopes with immune targeting, offers a solution. However, the lack of flexible systems targeting tumor antigens to cross-presenting dendritic cells (DCs) limits clinical development. Although antigen-anti-Clec9A mAb conjugates target cross-presenting DCs, adjuvant must be codelivered for cytotoxic T lymphocyte (CTL) induction. We functionalized tailored nanoemulsions encapsulating tumor antigens to target Clec9A (Clec9A-TNE). Clec9A-TNE encapsulating OVA antigen targeted and activated cross-presenting DCs wi..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
The work was supported by National Health and Medical Research Council (NHMRC) grants 1083192, 1082665, and 1083747, and by a grant from the Australian Skin and Skin Cancer Centre. RT was supported by Arthritis Queensland and an NHMRC Research Fellowship. ML and IC were supported by a Bill and Janina Amiet Fellowship. We thank Christian Engwerda (QIMR Berghofer) and Ian Frazer (Diamantina Institute, University of Queensland) for supplying mice and Hendrik Nel for technical assistance.